Viking Therapeutics, Inc.
VKTX
शेयरों में रैंक
#4520
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
शेयर मूल्य
$25.99
मार्केट कैप
$3.31B
बदलाव (1 दिन)
-1.47%
बदलाव (1 वर्ष)
-17.27%
देश
US
व्यापार Viking Therapeutics, Inc. (VKTX)
श्रेणी
Healthcare
Viking Therapeutics, Inc. (VKTX) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $27.52 (2026-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $8.59 (2015-04-01 को)
दिन का सबसे निम्न समापन मूल्य: $8.59 (2015-04-01 को)
Viking Therapeutics, Inc. के स्टॉक मूल्य का इतिहास 2015 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
| वर्ष | प्रदर्शन |
|---|---|
| 2026 (TTM) | -7.92% |
| 2025 | -20.83% |
| 2024 | 152.59% |
| 2023 | 215.71% |
| 2022 | 16.84% |
| 2021 | -21.08% |
| 2020 | -20.48% |
| 2019 | -10.51% |
| 2018 | 130.53% |
| 2017 | 246.93% |
| 2016 | -60.36% |
| 2015 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
| कंपनी | स्टॉक मूल्य | परिवर्तन 1व% | देश |
|---|---|---|---|
| $536.74 | 25.87% |
US
|
|
| $227.23 | 746.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.75 | 8.30% |
NL
|
